KR20180032506A - Composition comprising peptide derived from thioredoxin-interacting protein or polynucleotide encoding the peptide for rejuvenation of stem cell - Google Patents

Abstract

The present invention relates to a pharmaceutical composition for reverse aging of aged stem cells, wherein the pharmaceutical composition contains a peptide derived from thioredoxin-interacting protein (TXNIP) or a polynucleotide encoding the same as an active ingredient. It has been confirmed that the peptide derived from TXNIP increases engraftment of aged hematopoietic stem cells (HSC), deceases a serial biasing tendency, decreases a long-term HSC (LT-HSC) ratio, and suppresses p38 and ROS in a mouse in which competitive transplantation is performed by using aged HSCs compared to a control group which is not treated with a peptide. Thus, it has been confirmed that the characteristics of aged HSCs are suppressed, and it has been confirmed that administration of a peptide derived from TXNIP increases the proliferation of leukocytes of an aged mouse to a level of a young mouse in an acute leucopenia model. In addition, it has been confirmed that the peptide derived from TXNIP recovers an extremity phenomenon of Cdc42 in aged HSCs, decreases expression of p16, p19, p21, and Wnt5a which are aging-related genes, and increases homing of HSCs. Accordingly, the peptide derived from TXNIP of the present invention can be useful as a composition for reverse aging of HSCs.

Description

[0001] The present invention relates to a composition for reverse aging of aging stem cells containing a thioredoxin binding protein derived peptide or a polynucleotide encoding the same, and a use thereof.

The present invention relates to a pharmaceutical composition for reverse-aging of aging stem cells, which contains, as an active ingredient, a peptide derived from a thioredoxin-interacting protein (TXNIP) or a polynucleotide encoding the same.

Aging is a natural phenomenon that occurs throughout life in a living organism, and most older people are suffering from aging-related diseases. To treat these aging-related diseases, there is a method of rejuvenating stem cells. Recently, studies on the aging of stem cells have been conducted, and methods of rejuvenating stem cells have been reported.

Stem cells are divided into embryonic stem cells (ES cells) and adult stem cells depending on the possibility of differentiation. Embryonic stem cells have a pluripotent potential to differentiate into cells of all tissues On the other hand, adult stem cells are multipotent stem cells that are specific to each organs obtained from the placenta at the stage of the development of the organs of the adult or embryo, and their pluripotency is generally limited to the cells constituting the tissue. . These adult stem cells remain in most organs after becoming adults, compensating for the loss of normal or pathologically occurring cells. When the stem cells become old, the tissues become old, the function of maintaining the homeostasis becomes weak, and the tissue regeneration is reduced.

Hematopoietic stem cells (hematopoietic stem cells, HSC) are representative adult stem cells that can differentiate into all kinds of hematopoietic cells and provide blood cells for a lifetime. Hematopoietic stem cells produce blood over a lifetime and exhibit a high turnover. When the hematopoietic stem cell grows older, immune function falls and an aging-related disease occurs.

HSCs are differentiated into different types of hematopoietic progenitor cells according to their differentiation stage. LTC-HSC (long-term HSC) is located at the highest level in HSC differentiation hierarchy. The hematopoiesis is continued to replenish the hematopoietic system which is differentiable and permanently. ST-HSC (short-term HSC) has the ability to self-replicate and differentiate into all the blood cells present in the body, but unlike LT-HSC, the duration of hematopoietic action is short and MPP (multipotent progenitor) . However, LT-HSC and LT-HSC do not have self-replicating ability. In other words, LT-HSC, ST-HSC, and MPP decrease the self-replicating ability as stem cells. These three types of hematopoietic progenitor cells are characterized by expressing Sca1 and c-Kit without lineage expression (Lineage ^- Sca1 ⁺ c-kit ⁺ ) and different stages of HSC are distinguishable and are collectively referred to as LSK cells. Furthermore, when MPP is further differentiated, it divides into myeloid progenitor CMP (common myeloid progenitor) and lymphoid progenitor cell CLP (common lymphoid progenitor), and CMP differentiates into megakeryocyte-erythroid progenitor (MEP) and granulocyte-monocyte progenitor ), And finally differentiate into myeloid cells such as red blood cells, giant cells and eosinophils, and CLP differentiates into lymphocytic cells such as B cells, T cells and NK cells.

However, in the case of adult stem cells, stem cells become aging due to aging of the body, and their functional activity or homeostasis are not maintained. The characteristics of senescent HSCs are known to increase LT-HSC, decrease B-cells, increase lineal skewing, and increase ROS (Florian et al., 2012, Cell stem cell, 10 , 520-530; Montecino-Rodriguez et al., 2013, The Journal of Clinical Investigation, 123, 958-965). As HSC ages, the production of blood cells decreases, leading to a decrease in immune function and can cause various diseases. Therefore, if the aged HSC can be reverse aged to maintain self-replication and hematopoiesis, it will be the basis of a healthy immune system and it will be a great help in the treatment or prevention of diseases.

In a number of studies, it has been reported that aged mice undergo major changes in the hematopoietic system. ^{CD34 - / Flk2 - / LSK (} Lineage - / C-kit / + Sca-1 +) cells (LT-HSC) increases, and occur a lineage skewing (line deflection), increased reactive oxygen species (ROS), and peripheral Leukocytes decrease in blood vessels. When HSC grows older, mitochondrial DNA damage, increased ROS and p38, DNA damage, telomere shortening, epigenetic alteration, loss of Cdc 42 polarity, increased Wnt-5a, and cloning stress occur. Recently, a method of regenerating HSC by inhibiting Cdc42 activity has been reported.

Thioredoxin-interacting protein (TXNIP) is an inhibitor of thioredoxin and is also known as a tumor suppressor because it inhibits cell cycle progression (Han et al., 2003, Oncogene, 22, 4035 -4046), and increased resistance to active oxygen has been disclosed as a therapeutic agent for active oxygen-related diseases (WO013159879). In addition, it has been reported that TXNIP is induced by the decrease of p38 and JNK, leading to the final differentiation of erythrocytes (Gasiorek J. et al., 2015, Experimental Hematology, 43, 393-403) It has been reported that the number of hematopoietic stem cells is reduced in knockout mice, but the function of TXNIP stem cell retrogradation has not been disclosed.

Therefore, the present inventors tried to find a way to restore the function of aged HSC, and found that peptides derived from thioredoxin-interacting protein (hereinafter referred to as TXNIP) competitively transplant HSC of old age ), Increased engraftment of old HSCs, increased Myeloid, decreased B-cell decreasing tendency, decreased LT-HSC ratio, decreased p38 activity and ROS compared to the control without TXNIP In addition, the administration of the TXNIP-derived peptide in the acute leukopenia model confirmed that the leukocyte proliferation of the old mice was promoted to the level of the young mouse, and also the depolarization phenomenon of Cdc42 in the senescent HSC was restored, , P16, p19, p21 and Wnt5a, and increased the homing of HSC.

The present inventors have found that thioredoxin-interacting protein (hereinafter referred to as TXNIP) interacts with p38 MAPK (mitogen-activated protein kinase) to regulate HSC senescence. In particular, TXNIP-p38-interacting motif peptides inhibit the activity of p38 to reduce reactive oxygen species (ROS) and convert aged HSCs into young HSCs in vivo and in vitro, And the peptide can be used as a preventive and therapeutic agent for aging-related diseases, thereby completing the present invention.

An object of the present invention is to provide a pharmaceutical composition for the reverse aging of stem cells comprising a peptide derived from a thioredoxin-interacting protein (TXNIP) or a polynucleotide encoding the same as an active ingredient.

In order to achieve the above object, the present invention provides a peptide comprising any one selected from the amino acid sequences represented by SEQ ID NOS: 2, 3, 4 and 5.

The present invention also provides a fusion peptide of a peptide comprising any one selected from the amino acid sequences of SEQ ID NOS: 2, 3, 4, and 5 and a TAT peptide comprising the sequence of SEQ ID NO: 9.

The present invention also relates to a peptide derived from a thioredoxin-binding protein which interacts with a thioredoxin-interacting protein (TXNIP) or p38 MAPK (mitogen-activated protein kinase) or a polynucleotide encoding them By weight of the composition.

The present invention also provides a composition for inhibiting stem cell senescence comprising, as an active ingredient, a thioredoxin binding protein or a peptide derived from a thioredoxin binding protein which interacts with p38 MAPK, or a polynucleotide encoding these.

In addition, the present invention provides a pharmaceutical composition for the prevention and treatment of geriatric diseases containing as an active ingredient a thioredoxin binding protein or a peptide derived from a thioredoxin binding protein which interacts with p38 MAPK, or a polynucleotide encoding them .

The present invention also provides a screening method for a drug for inhibiting stem cell senescence comprising the following steps.

1) treating a test substance with stem cells lacking a thioredoxin-interacting protein (TXNIP); And

2) selecting a test substance exhibiting any one or more characteristics selected from the group consisting of the following items a to d as compared to a control group not treated with the test substance;

a. reduction of expression or activity of p16, p19, p21 or Wnt5a gene;

b. reduction of phosphorylation of p38;

c. Reduced levels of reactive oxygen species (ROS); And

d. Increased polarity of Cdc42 (cell division control protein 42 homolog).

The present invention also provides an anti-aging health functional food comprising a thioredoxin binding protein or a peptide derived from thioredoxin binding protein interacting with p38 MAPK, or a polynucleotide encoding them, as an active ingredient.

In addition, the present invention provides an anti-aging cosmetic composition comprising as an active ingredient, a thioredoxin binding protein or a peptide derived from thioredoxin binding protein which interacts with p38 MAPK, or a polynucleotide encoding the same.

The present invention also relates to a method of treating a geriatric disease by administering to a patient a pharmaceutically effective amount of a thioredoxin binding protein or a composition comprising a thioredoxin binding protein derived peptide interacting with p38 MAPK or a polynucleotide encoding the same ≪ / RTI >

The present invention also provides the use of the thioredoxin binding protein derived peptides, or polynucleotides encoding them, that interact with thioredoxin binding protein or p38 MAPK in the manufacture of a medicament for the treatment of geriatric diseases.

The present invention also provides a thioredoxin binding protein or a polynucleotide encoding thioredoxin binding protein-derived peptide interacting with p38 MAPK for use in the treatment of geriatric diseases.

In the present invention, peptides derived from thioredoxin-interacting protein (TXNIP) competitively transplant old age HSCs to increase the engraftment of old HSCs compared to the control without peptide, , Decreased LT-HSC ratios, decreased p38 activity and ROS, and administration of TXNIP-derived peptides enhanced leukocyte proliferation in older mice to young mouse levels in acute leukopenia models , Confirming that the senescence-related genes p16, p19, p21 and Wnt5a expression were reduced and HSC homing was increased by restoring the polarizing phenomenon of Cdc42 in aged HSCs, The peptide derived from a single binding protein can be usefully used as a composition for reverse aging of hematopoietic stem cells.

Figure 1 shows the inhibitory effect of p38 on the binding of p38 to a peptide derived from TXNIP (thioredoxin interacting protein). FIG. 1A shows the GST-full down analysis of GST-TXNIP-T and p38. FIG. 1B shows the inhibitory effect of p38 on the phosphorylation enzyme activity by GST-TXNIP-T treatment by in vitro kinase assay FIG. 1C shows GST-full down analysis of TXNIP-derived peptides (TN12, TN13, TN14, TN15) and p38, FIG. 1D is a graph showing the phosphorylation of AT13 p38 < / RTI >
Figure 2 shows the modulation of activity by mutual binding with p38 of TAT-TN13. FIG. 2A shows the interaction between TAT-TN13 and p38 through isothermal titration calorimetry (ITC) analysis. FIG. 2B shows that TAT does not bind to p38 as a control, and FIG. 2C shows that aged bone marrow cells 2 shows the effect of ATF-2 phosphorylation inhibition on p38 activity of TAT-TN13 and substrate protein of p38.
Figure 3 shows bone marrow cell senescence in TXNIP knockout (TXNIP ^{- / -} ) mice. Figure 3A is a diagram confirming TXNIP mRNA expression in the cells constituting the bone marrow, and Figure 3B is from 12 months mice TXNIP showing the effect on stem cells (hematopoietic stem cell, HSC) ratios typical road TXNIP ^{+ / +} And HSC, ST-HSC and MPP in the TXNIP ^{- / -} bone marrow by flow cytometry. FIG. 3C shows the LT-HSC, ST-HSC and MPP ratios by flow cytometry at various ages.
FIG. 4 shows expression of HSC aging index ROS (A) or p16 (B), p19 (C), p21 (D) or Wnt5a (E) mRNA in hematopoietic stem cells (HSCs).
5 is a graph showing the anti-aging effect of TXNIP on hematopoietic stem cells. 5B is a graph showing the survival rate after induction of acute leukopenia, and FIGS. 5C to 5G are graphs showing survival rates after competitive induction in TXNIP ^{+ / +} and TXNIP- ^{/ -} . FIG. 5A is a graph showing changes in blood leukocyte count after induction of acute leukopenia, (E), the composition of LSK (Lin ^- / Sca - 1 ⁺ / c - Kit ⁺ ) cells (F), the activity of free radicals (G) in the peripheral blood (C) and bone marrow ).
Figure 6 shows the interaction of TXNIP with p38 phosphorylase. FIG. 6A shows mRNA expression of p38 homologous proteins in bone marrow cells. FIGS. 6B to D show p-p38 expression in TXNIP ^{+ / +} and TXNIP- ^{/ -} by flow cytometry (B), immunofluorescence staining (C) Western blot (D). FIG. 6E shows the expression of TXNIP according to the age of LT-HSC by immunofluorescence staining.
Figure 7 shows the mutual binding and binding sites of TXNIP and p38 phosphorylase. FIG. 7A is a graph showing that TXNIP and p38 bind to each other by immunoprecipitation using a TXNIP antibody. FIG. 7B is a graph showing the binding of TXNIP and p38 in HSC through in situ proximity ligation (PLA) FIG. 7C is a graph showing changes in expression of TXNIP and p-p38 (p38 phosphorylation) by active oxygen, and FIG. 7D is a result of in situ PLA showing interaction between p38 and TXNIP by age and active oxygen in HSC , FIG. 7E shows GST-full down results confirming that the increase in the interaction of TXNIP with p38 by active oxygen is not related to the p38 phosphorylation capacity (kinase dead). FIGS. 7F to G show TXNIP F) and p38 (G).
8 is a graph showing the inhibitory effect of TAT-TN13 on the activity of p38 phosphorylase. 8A shows that the phosphorylation of p38 is reduced when the aged HSCs are treated with TAT-TN13 peptide. Fig. 8B to C show the binding activity of p38 with MKK3 (C) and MKK6 (D) phosphorylating p38 TAT-TN13 peptide. Fig. 8D shows that the binding of p38 to TXNIP is reduced when the aged bone marrow is treated with TAT-TN13 peptide by immune sedimentation.
9 is a graph showing an anti-aging effect of hematopoietic stem cells by inhibition of the activity of p38 phosphorylase. FIG. 9A is a graph showing the engraftment of CD45.2 ⁺ in peripheral blood after competitive transplantation, FIG. 9B is an analysis of post-competitive deflection, FIG. 9C is a graph showing LSK (Lin ^- / Sca - 1 ⁺ c-Kit ⁺⁾ is a diagram showing the configuration of a cell, Figure 9D is a diagram showing the expression of p-p38, Figure 9E is a diagram showing the radical change, FIG 9F is 2 and 12 months command line deflection of mice FIG. 9G is a graph showing the survival rate after induction of acute leukopenia.
10 is a graph showing the effect of TXNIP-derived peptide TAT-TN13 on the hematopoietic stem cell senescence by inhibition of p38 phosphorylase in vitro. FIGS. 10A to H are graphs showing p-p38 expression (A), active oxygen level (B) and polarity (C) of Cdc42 after treatment of aged hematopoietic stem cells with TAT-TN13, E), p21 (F), and Wnt5a (G) mRNA expressing short-term progeny (H) of hematopoietic stem cells in vivo.
11 is a graph showing in vivo HSC reverse aging effect of a TXNIP-derived peptide TN13 expressed in a plasmid gene. 11A to E show competitive transplantation of CD45.2 ⁺ hematopoietic stem cells transfected with the TN13 peptide followed by transplantation of transplanted cells (A), sequence defects (B), and LSK (Lin ^- / Sca- 1 ⁺ / c-Kit ⁺⁾ configuration of the cell (c), is a diagram showing a p-p38 expression (D), active oxygen level (E).
Figure 12 shows the in vivo reverse transcriptional activity of the TXNIP-derived peptide TAT-TN13. 12A to E show the results of competitive transplantation of old CD45.2 ⁺ hematopoietic stem cells treated with TAT-TN13 peptide in vitro, followed by transplantation cell engraftment (A), sequence biases (B) ^{(Lin - / Sca-1 +} / c-Kit +) a diagram showing a configuration (c), p-p38 expression (D), active oxygen level (E) of the cell, and then FIG. 12F is induced acute leukopenia TAT- Figure 7 shows changes in leukocyte counts by TN13 treatment.
FIG. 13 is a Western blot image showing inhibition of p38 MAPK activity in bone marrow cells of TN13, a peptide fragment derived from TXNIP (thioredoxin interacting protein) binding to p38 MAPK.
FIG. 14 shows the results of measurement of the amount of inflammatory cytokine secreted by Raw264.7 macrophages induced by LPS according to the concentration of TN13. (A) IL-1β cytokine production amount (B) IL-6 cytokine (C) TNF- [alpha] cytokine production amount.
Fig. 15 is a graph showing the results of confirming that TN13 peptide treatment effectively inhibited p38 MAPK activity, thereby also inhibiting the activity of NF-kB (p65), an inflammatory regulatory factor, and c-Jun.
Fig. 16 is a graph showing the results of inhibiting iNOS and COX-2 protein expression effectively in Raw264.7 macrophages induced by LPS induced TN13 peptide treatment.
FIG. 17 is a graph showing the results of suppression of NO production in macrophages by treatment with TN13 peptide. FIG.
FIG. 18 shows the results of differentiation into mature osteoclasts by M-CSF and RANKL staining with TRAP (tartrateresistant acid phosphatase) solution to show osteoclast differentiation inhibition by TN13 peptide treatment (A) 264.7 cell to mature osteoclast differentiation (B) osteoclast-derived osteoclast precursor to mature osteoclast differentiation.
FIG. 19 (A) shows an experimental schedule of an experiment using an ovariectomy osteoporosis model using an estrogen-deficient mouse, FIG. 19 (B) shows a three-dimensional image of the femur in the above experimental model, (OVX) after osteoporosis induction, and TN13 after osteoporosis induction.
FIG. 20 is a histomorphometric examination of histological specimens of the left femur in an ovariectomized osteoporosis model using estrogen-deficient mice. (A) Bone mineral density of soju bone. (B) Number of shochu scales. (C) Bony surface. (D) Bone volume / total volume. (E) Bone surface / total volume.

Hereinafter, the present invention will be described in detail.

The present invention provides a peptide comprising any one selected from the amino acid sequences of SEQ ID NOS: 2, 3, 4 and 5. Preferably, a peptide comprising the amino acid sequence of SEQ ID NO: 3 is provided.

The peptide according to the present invention is a peptide sequence which binds to and interacts with p38 MAPK (mitogen-activated protein kinase) as a part of a thioredoxin-interacting protein (TXNIP). According to the present invention, the sequence of thioredoxin-binding protein capable of interacting with p38 was first identified, and it has an action effect such as anti-aging, inhibition of senescence of stem cells, leukocyte proliferation and reduction of senescence-related genes . Through these actions and effects, it is possible to prevent and treat geriatric diseases, to inhibit the aging of stem cells, and to reverse the aging process.

The present invention also provides a fusion peptide of a peptide comprising any one selected from the amino acid sequences of SEQ ID NOS: 2, 3, 4, and 5 and a TAT peptide comprising the sequence of SEQ ID NO: 9. Preferably a peptide comprising the amino acid sequence of SEQ ID NO: 3 and a fusion peptide of the TAT peptide consisting of the sequence of SEQ ID NO: 9.

The peptide may be a peptide derived from a thioredoxin-interacting protein (TXNIP).

The thioredoxin-binding protein-derived peptide used in the present invention may be derived from an animal, a plant, or a microorganism, and preferably is a thioredoxin-binding protein derived from a human. However, the peptides derived from a thioredoxin- Derived protein.

Such proteins may additionally be modified such as phosphorylation, acetylation, methylation, glycosylation, etc., and may bind to other proteins, but they may be the same as the proteins before modification as long as they do not change to such an extent that the function of the protein is lost .

The TAT peptide preferably binds to the end of a peptide comprising an amino acid sequence represented by SEQ ID NO: 2, 3, 4 or 5, and the end is an amino terminal (5 'terminal, N-terminal) or a carboxy terminal Terminal, C-terminal), but most preferred is the amino terminal (5 'terminal, N-terminal).

The thioredoxin binding protein is a protein represented by SEQ ID NO: 1, or a protein having the same activity as the protein or having a gene position encoding the thioredoxin binding protein on the chromosome is equal to or more than one, Addition, deletion, or substitution.

Wherein the thioredoxin binding protein has at least 80% homology, more specifically at least 90% homology, most specifically at least 95%, 96%, 97%, 98%, 99% or 99.5% homology to the amino acid sequence of SEQ ID NO: But are not limited thereto.

The present invention also relates to a peptide derived from a thioredoxin-binding protein which interacts with a thioredoxin-interacting protein (TXNIP) or p38 MAPK (mitogen-activated protein kinase) or a polynucleotide encoding them By weight of the composition.

Peptides derived from thioredoxin binding protein that preferably interact with thioredoxin-interacting protein (TXNIP) or p38 MAPK (mitogen-activated protein kinase) in a reverse-aging composition are SEQ ID NOS: 2, 3, 4 and 5 , More preferably a fusion peptide comprising the TAT peptide consisting of the sequence of SEQ ID NO: 9.

The present invention also provides a composition for inhibiting stem cell senescence comprising, as an active ingredient, a thioredoxin binding protein or a peptide derived from a thioredoxin binding protein which interacts with p38 MAPK, or a polynucleotide encoding these.

Preferably, the thioredoxin binding protein-derived peptide interacting with thioredoxin-interacting protein (TXNIP) or p38 MAPK (mitogen-activated protein kinase) in a composition for inhibiting stem cell senescence has a peptide sequence of SEQ ID NO: 4 and 5, more preferably a fusion peptide comprising the TAT peptide consisting of the sequence shown in SEQ ID NO: 9.

In addition, the present invention provides a pharmaceutical composition for the prevention and treatment of geriatric diseases containing as an active ingredient a thioredoxin binding protein or a peptide derived from a thioredoxin binding protein which interacts with p38 MAPK, or a polynucleotide encoding them .

Preferably, a thioredoxin-binding protein derived peptide interacting with a thioredoxin-interacting protein (TXNIP) or a p38 MAPK (mitogen-activated protein kinase) in a pharmaceutical composition for the prevention and treatment of geriatric disease comprises SEQ ID NO: 2, 3, 4 and 5, and more preferably a fusion peptide comprising the TAT peptide consisting of the sequence of SEQ ID NO: 9.

The geriatric disease is preferably one or more selected from the group consisting of dementia, hypertension, Parkinson's disease, diabetes, cataract, osteoporosis, stroke, periodontal disease and degenerative arthritis, but is not limited thereto. Preferably the geriatric disease is osteoporosis, or degenerative arthritis.

The present invention also provides a pharmaceutical composition for the prevention and treatment of inflammatory diseases containing, as an active ingredient, a thioredoxin binding protein or a peptide derived from a thioredoxin binding protein which interacts with p38 MAPK, or a polynucleotide encoding them. The inflammation is one of defensive reactions of biological tissues against certain stimuli, and is a biologic defense mechanism for recovering to its original state by eliminating injuries caused by various harmful stimuli. Examples of inflammatory diseases include, but are not limited to, inflammation and gastritis, colitis, arthritis, nephritis, hepatitis, arteriosclerosis, or degenerative diseases.

The thioredoxin-binding protein-derived peptide preferably includes the amino acid sequence of any one selected from the group consisting of SEQ ID NOS: 2 to 5, but is not limited thereto.

The thioredoxin-binding protein-derived peptide is preferably bound to a TAT peptide represented by SEQ ID NO: 9 at its N-terminus but is not limited thereto.

The thioredoxin-binding protein-derived peptide is preferably encoded by a polynucleotide sequence represented by any one of SEQ ID NOS: 42 to 45, but is not limited thereto.

Compositions of the present invention may also include carriers, diluents, excipients, or a combination of two or more thereof commonly used in biological formulations. The pharmaceutically acceptable carrier is not particularly limited as long as the composition is suitable for in vivo delivery, for example, Merck Index, 13th ed., Merck & Inc. A buffered saline solution, a buffer solution, a dextrose solution, a maltodextrin solution, glycerol, ethanol, and one or more of these components may be mixed and used, and if necessary, an antioxidant, a buffer, Conventional additives may be added. In addition, diluents, dispersants, surfactants, binders, and lubricants may be additionally added to formulate into main dosage forms such as aqueous solutions, suspensions, emulsions, etc., pills, capsules, granules or tablets. Further, it can be suitably formulated according to each disease or ingredient, using the method disclosed in Remington's Pharmaceutical Science (Mack Publishing Company, Easton PA, 18th, 1990) in a suitable manner in the art.

The composition of the present invention may further contain one or more active ingredients showing the same or similar functions. The composition of the present invention contains 0.0001 to 10% by weight, preferably 0.001 to 1% by weight of the protein, based on the total weight of the composition.

The composition of the present invention may be administered orally or parenterally (for example, intravenously, subcutaneously, intraperitoneally or topically) orally, and the dose may be appropriately determined depending on the body weight, age, sex, The range varies depending on diet, administration time, method of administration, excretion rate, and severity of the disease. The daily dose of the composition according to the present invention is 0.0001 to 10 mg / ml, preferably 0.0001 to 5 mg / ml, more preferably administered once to several times a day.

The therapeutically effective amount of the composition of the present invention may vary depending on a variety of factors, such as the method of administration, the site of administration, the condition of the patient, and the like. Therefore, when used in the human body, the dosage should be determined in consideration of safety and efficacy. It is also possible to estimate the amount used in humans from the effective amount determined through animal experiments. These considerations in determining the effective amount are described, for example, in Hardman and Limbird, eds., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 10th ed. (2001), Pergamon Press; And E.W. Martin ed., Remington's Pharmaceutical Sciences, 18th ed. (1990), Mack Publishing Co.

In the present invention, the function of TXNIP in the senescence of hematopoietic stem cells (HSCs) using TXNIP ^{- / -} mice was determined. The senescence of TXNIP ^{- / -} HSC occurs by reactive oxygen species (ROS) or p38 activity. The present invention relates to a method for inhibiting senescence of HSC by inhibiting the activity of p38 by binding TXNIP to p38, . In addition, it was confirmed that TXNIP-derived TN13 peptide and TAT-TN13 peptide were inhibited p38 and suppressed senescence of HSC. Thus, it can be usefully used as a composition for prevention of aging diseases and anti-aging composition by aging stem cells Respectively.

In a specific example of the present invention, a domain fragment of four thioredoxin-interacting proteins (TXNIP) was prepared and confirmed that the peptide binds to p38 (see FIG. 1), and intracellular penetration efficiency (Fig. 2). In the TXNIP knockout mice, a fusion peptide in which an HIV TAT transduction domain sequence was bound to the TXNIP domain fragment TN13 was prepared and bound to p38 to inhibit the activity of p38 The aging-related genes p16, p19, p21 and Wnt5a expression, p38 phosphorylation and active oxygen levels were increased (see Fig. 4), and HSCs were analyzed by flow cytometry of hematopoietic stem cells (HSC) , Confirming that the hematopoietic action is inhibited (see FIG. 5), suggesting that TXNIP has an effect of preventing aging. TXNIP also interacted with p38 and oxidative stress confirmed that TXNIP enhanced p38 interaction (see Figures 6 and 7) and TXNIP ^{- / -} / p38 ^{AF / +} mice (TXNIP knockout / p38 (See FIG. 8), confirming that TXNIP-derived peptides inhibit the activity of p38 by docking with p38 (see FIG. 9) and inhibiting the aging of HSCs by inhibition of TAT-TN13 fusion peptide (See Fig. 10C), and the expression of the senescence-related genes p16, p19, p21 and Wnt5a (see Fig. 10D-G) was treated with senescent HSCs in vitro to recover the polarization phenomenon of Cdc42 (see Fig. 10H), and it was confirmed that the aged mice were treated with TN13 peptide or TAT-13 peptide in vivo to reverse the aging of HSC (see Figs. 11 and 12).

Therefore, TXNIP interacts with p38 to inhibit the activity, thereby preventing the senescence of HSC and reverse aging the aged HSC. The TXNIP-derived peptide or the polynucleotide encoding the same is useful as a pharmaceutical composition for aging stem cell senescence, Compositions for inhibiting cell senescence, and pharmaceutical compositions for the prevention and treatment of geriatric diseases.

In addition,

1) treating a test substance with stem cells lacking a thioredoxin-interacting protein (TXNIP); And

2) selecting a test substance exhibiting any one or more characteristics selected from the group consisting of the following items a to d as compared to a control group not treated with the test substance: .

a. reduction of expression or activity of p16, p19, p21 or Wnt5a gene;

b. reduction of phosphorylation of p38;

c. Reduced levels of reactive oxygen species (ROS); And

d. Increased polarity of Cdc42 (cell division control protein 42 homolog).

In a specific example of the present invention, the TXNIP-derived peptide restored the polarization phenomenon of Cdc42 in old HSCs in the old HSC, and the expression of the senescence-related genes p16, p19, p21 and Wnt5a (See FIG. 10D-G) and confirming that the homing of the HSC is increased (see FIG. 10H), the present invention provides a thioredoxin binding protein-derived peptide that interacts with thioredoxin binding protein or p38 MAPK Can be used to screen for drugs for inhibiting stem cell senescence.

The present invention also provides an anti-aging health functional food comprising a thioredoxin binding protein or a peptide derived from thioredoxin binding protein interacting with p38 MAPK, or a polynucleotide encoding them, as an active ingredient.

The thioredoxin-binding protein-derived peptide preferably includes the amino acid sequence of any one selected from the group consisting of SEQ ID NOS: 2 to 5, but is not limited thereto.

The thioredoxin-binding protein-derived peptide is preferably bound to a TAT peptide represented by SEQ ID NO: 9 at its N-terminus but is not limited thereto.

The thioredoxin-binding protein-derived peptide is preferably encoded by a polynucleotide sequence represented by any one of SEQ ID NOS: 42 to 45, but is not limited thereto.

As used herein, the term "health functional food" is produced by using raw materials or ingredients (functional raw materials) having functions useful for nutrients or human body that are likely to be deficient in daily eating, and is intended to maintain the normal function of the human body, But is not limited to, and is not meant to exclude health food in the usual sense.

The health functional food of the present invention can be used as it is or in combination with other food or food ingredients, and can be suitably used according to conventional methods.

In addition, the health functional food of the present invention further comprises a pharmaceutically acceptable food-aid additive. Food-acceptable food supplementary additives that may be used in the present invention include sugars such as glucose, fructose, maltose, sucrose, dextrin, cyclodextrins, natural carbohydrates such as sugar alcohols such as xylitol, sorbitol, erythritol, Natural flavors such as martin and stevia extract, synthetic flavors such as saccharin and aspartame, colorants, pectic acid or its salts, alginic acid or its salts, organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, glycerin , Alcohols, carbonating agents, and the like, but are not limited thereto.

In addition to the above, the health functional food of the present invention may contain flavoring agents such as various nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavors, colorants, and thickening agents (cheese, chocolate, etc.).

In addition, the present invention provides an anti-aging cosmetic composition comprising as an active ingredient, a thioredoxin binding protein or a peptide derived from thioredoxin binding protein which interacts with p38 MAPK, or a polynucleotide encoding the same.

The thioredoxin-binding protein-derived peptide preferably includes the amino acid sequence of any one selected from the group consisting of SEQ ID NOS: 2 to 5, but is not limited thereto.

The thioredoxin-binding protein-derived peptide is preferably bound to a TAT peptide represented by SEQ ID NO: 9 at its N-terminus but is not limited thereto.

The thioredoxin-binding protein-derived peptide is preferably encoded by a polynucleotide sequence represented by any one of SEQ ID NOS: 42 to 45, but is not limited thereto.

The cosmetics manufactured from the cosmetic composition of the present invention can be prepared in the form of a general emulsified formulation and a solubilized formulation. Cosmetics of the emulsified form include nutritive lotion, cream, essence and the like, and the cosmetics of the solubilized form include the flexible lotion. In addition to cosmetics containing the extracts of cinnamon and cinnamon of the present invention, dermatologically acceptable mediums or bases can be prepared to be formulated into topical or systemic adjuvants conventionally used in the field of dermatology.

In addition, the cosmetic composition of the present invention may further comprise, in addition to the peptide derived from thioredoxin binding protein, a lipid, an organic solvent, a solubilizing agent, a thickening agent and a gelling agent, a softening agent, an antioxidant, a suspending agent, a stabilizer, a foaming agent, Surfactants, water, ionic or nonionic emulsifiers, fillers, sequestering and chelating agents, preservatives, vitamins, barrier agents, wetting agents, essential oils, dyes, pigments, lipophilic or lipophilic active agents, lipid vesicles or cosmetics Or any other ingredient conventionally used in cosmetics or dermatology. And the above ingredients may be introduced in amounts commonly used in the dermatology field.

The cosmetic composition of the present invention can be used as a skin lotion, a skin softener, a skin toner, an astringent, a lotion, a milk lotion, a moisturizing lotion, a nutrition lotion, a massage cream, a nutritive cream, a moisturizing cream, a hand cream, , Cleansing foam, cleansing lotion, cleansing cream, body lotion, body cleanser, emulsion, press powder, loose powder, eye shadow and the like.

The present invention provides a method of treating a geriatric disease by administering to a patient a pharmaceutically effective amount of a composition containing a thioredoxin binding protein or a peptide derived from a thioredoxin binding protein that interacts with p38 MAPK or a polynucleotide encoding the same . Preferably, the thioredoxin-binding protein derived peptide interacting with thioredoxin-interacting protein (TXNIP) or p38 MAPK (mitogen-activated protein kinase) comprises an amino acid sequence as set forth in SEQ ID NOS: 2, 3, 4 and 5 , More preferably a fusion peptide comprising a TAT peptide consisting of the sequence of SEQ ID NO: 9.

The present invention provides the use of the thioredoxin binding protein derived peptides, or polynucleotides encoding them, which interact with thioredoxin binding protein or p38 MAPK in the manufacture of a medicament for the treatment of geriatric diseases. Preferably, the thioredoxin-binding protein derived peptide interacting with thioredoxin-interacting protein (TXNIP) or p38 MAPK (mitogen-activated protein kinase) comprises an amino acid sequence as set forth in SEQ ID NOS: 2, 3, 4 and 5 , More preferably a fusion peptide comprising a TAT peptide consisting of the sequence of SEQ ID NO: 9.

The present invention provides a thioredoxin binding protein or a polynucleotide encoding thioredoxin binding protein-derived peptide interacting with p38 MAPK for use in the treatment of geriatric diseases. Preferably, the thioredoxin-binding protein derived peptide interacting with thioredoxin-interacting protein (TXNIP) or p38 MAPK (mitogen-activated protein kinase) comprises an amino acid sequence as set forth in SEQ ID NOS: 2, 3, 4 and 5 , More preferably a fusion peptide comprising a TAT peptide consisting of the sequence of SEQ ID NO: 9.

The present invention relates to a method for treating inflammatory diseases by administering to a patient a pharmaceutically effective amount of a thioredoxin binding protein or a composition comprising a thioredoxin binding protein derived peptide interacting with p38 MAPK or a polynucleotide encoding the same . Preferably, the thioredoxin-binding protein derived peptide interacting with thioredoxin-interacting protein (TXNIP) or p38 MAPK (mitogen-activated protein kinase) comprises an amino acid sequence as set forth in SEQ ID NOS: 2, 3, 4 and 5 , More preferably a fusion peptide comprising a TAT peptide consisting of the sequence of SEQ ID NO: 9.

The present invention provides the use of the thioredoxin binding protein derived peptides, or polynucleotides encoding them, that interact with thioredoxin binding protein or p38 MAPK in the manufacture of a medicament for the treatment of inflammatory diseases. Preferably, the thioredoxin-binding protein derived peptide interacting with thioredoxin-interacting protein (TXNIP) or p38 MAPK (mitogen-activated protein kinase) comprises an amino acid sequence as set forth in SEQ ID NOS: 2, 3, 4 and 5 , More preferably a fusion peptide comprising a TAT peptide consisting of the sequence of SEQ ID NO: 9.

The present invention provides thioredoxin binding proteins for use in the treatment of inflammatory diseases or peptides derived from thioredoxin binding protein which interact with p38 MAPK, or polynucleotides encoding them. Preferably, the thioredoxin-binding protein derived peptide interacting with thioredoxin-interacting protein (TXNIP) or p38 MAPK (mitogen-activated protein kinase) comprises an amino acid sequence as set forth in SEQ ID NOS: 2, 3, 4 and 5 , More preferably a fusion peptide comprising a TAT peptide consisting of the sequence of SEQ ID NO: 9.

The matters mentioned in the use, composition and treatment method of the present invention are applied equally unless they are mutually contradictory.

Hereinafter, the present invention will be described in detail with reference to Examples and Experimental Examples.

EXAMPLES The following Examples and Experiments are for the purpose of illustrating the present invention, but the present invention is not limited by the following Examples and Experimental Examples.

[Example 1]

Thioredoxin Binding protein ( Thioredoxin - interacting protein , TXNIP ) Origin Pepta Id manufacture

<1-1> GST - TXNIP -T production

in - vitro a TXNIP construct (construct), GST-TXNIP- T for inhibiting p38 kinase activity to determine the interaction of TXNIP and p38 was produced from.

Specifically, the 150-317 amino acid fragment (GST-TXNIP-T; SEQ ID NO: 1) of TXNIP fused with GST and the His-tagged amino acid fragment The p38 protein was prepared, and its binding with p38 was confirmed by GST-full down analysis and western blot. The recombinant proteins expressed in E. coli, GST, GST-TXNIP (150-317) and His-p38 were purified by affinity chromatography. Dilute 5 ug of each protein with GST + His-p38 or GST-TXNIP (150-317) + His-p38 in a 1.5 ml tube containing 500 μl of cell lysis solution and add 20 μl of GST- C for 2 hours, and then washed 3 times with 1 ml of lysis solution. After removing the supernatant from the washed beads, the lysis solution and 5X SDS sample solution were added, heated at 100 ° C for 3 minutes, electrophoresed on SDS-PAGE gel, and western blotted. His-p38a was selectively bound to GST-TXNIP (150-317) by using an antibody with HRP attached to the primary antibody and ECL solution using secondary antibody. , The relative amount was confirmed by using the primary antibody? -GST as described above.

As a result, it was confirmed that GST-TXNIP-T binds to p38 (A in Fig. 1) and inhibits phosphorylation (p-ATF-2) of ATF-2, a lower signaling molecule of p38 , Confirming that GST-TXNIP-T inhibits the phosphorylating enzyme activity of p38.

<1-2> Construction of four TXNIP domain fragments

The present inventors also prepared four domain fragments of TXNIP (TN12; SEQ ID NO: 2, TN13; SEQ ID NO: 3, TN14; SEQ ID NO: 4 and TN15; SEQ ID NO: 5 ). Among these, TN13 was most strongly bound to P38 by GST-full down analysis (FIG. 1C). TN13 was found to bind to the docking region of P38 as well as MKK6 (SEQ ID NO: 6), MKK3b (SEQ ID NO: 7) and MEF2A (SEQ ID NO: 8) known to bind p38 (Fig.

[Table 1]

<1-3> Production of TAT-TN13 to increase permeation efficiency of peptide

In order to efficiently transfer the synthesized protein into cells, the inventors of the present invention synthesized an HIV TAT transduction domain sequence (SEQ ID NO: 9) at the N-terminus of TN13 produced in Example <1-2> To confirm the penetration efficiency of the peptide, TAT-TN13 peptide having FITC bound to the end of the TAT sequence was prepared. (P-p38 and p-ATF-2) of TAT-TN13 was confirmed by Isothermal titration calorimetry (ITC), and that TAT-TN13 peptide binds to P38 (Fig. 2C), confirming that TAT-TN13 effectively inhibited the phosphorylation enzyme activity of p38.

[Example 2]

Production of mutants of TXNIP and p38

Mutants of TXNIP and p38 were constructed to confirm the interaction of p38 with TXNIP. Was subjected to man TXNIP (NM_006472.5, SEQ ID NO: 10) or p38α (NM_139012, SEQ ID NO: 11) was used as a template using the primers shown in Table 2, the site-specific mutation (site-directed mutagenesis), the FLAG-CMV vector And introduced into cells.

[Table 2]

&Lt; Experimental Example 1 > TXNIP ^{- / -}  Aging of HSC

<1-1> TXNIP ^{- / -} Confirmation of HSC cell composition

In order to confirm the functionality of TXNIP from Stem Cell (Hematopoietic stem cells, HSC), bone marrow (bone marrow, BM) of the subset to configure and bone marrow ^{[Lin +, Lin -, MPP} (multipotent progenitor), ST-HSC ( (HSC), common lymphoid progenitor (CLP), common myeloid progenitor (CMP), granulocyte-monocyte progenitor (GMP), or megakeryocyte-erythroid progenitor (qPCR) of mRNA expression of TXNIP. Total RNA of cells was isolated using RNeasy Micro Kit (Qiagen). Quantitative real-time PCR was performed using SYBR Premix ExTaq (Takara Bio) and Thermal Cycler Dice Real Time System TP800 instrument (Takara Bio). Primers for amplification of the gene fragments are shown in Table 3.

[Table 3]

As a result, it was confirmed that the expression of TXNIP was significantly increased in LT-HSC (FIG. 3A).

To determine the effect of TXNIP on the senescence of HSCs, we analyzed the distribution of white blood cells by flow cytometry in peripheral blood of TXNIP ^{+ / +} (wild type) and TXNIP ^{- / -} (TXNIP konckout) mice. For analysis of flow cytometry, the femurs, tibias, hipbones or shoulder bones of the mice were pulverized to extract bone marrow cells and then suspended in RPMI1640 medium containing 2% fetal bovine serum (FBS) Respectively. Cultured bone marrow cells were analyzed by flow cytometry using FACSCanto II (BD Biosciences) and cells were isolated using FACSAria cell sorter (BD Biosciences). The following antibodies were used as cell surface markers or lineage markers for flow cytometry or cell isolation: anti-CD11b-biotin (clone M1 / 70, BD biosciences), anti-Gr-1-biotin Anti-CD1-biotin (clone PK136, BD biosciences), anti-CD2-biotin (RM2-5) anti-AT119 (BD biosciences), anti-Streptavidin-APC-eFluor780 (eBiosciences), anti-c-kit-PE (clone 2B8, BD biosciences) (Clone D7, BD biosciences), anti-Sca-1-APC (clone D7, eBiosciences), anti-CD34-FITC / Alexa Fluor 647 / PE (clone RAM34, BD (clone A20, eBiosciences) or anti-CD135-PE-Cy7 (clone A2F10.1, eBiosciences) -CD45.2-V500 (clone 104, BD biosciences). (Clone RA3-6B2, BD biosciences), anti-CD3e-APC-efluor780 (clone 17A2, eBiosciences), anti-CD3e-BV421 / PE-Cy7 (clone 17A2, 145-2C11 , BD biosciences), anti-Gr-1-Alexa Fluor 488 / eFluor 660 (clone RB6-8C5, eBiosciences), anti-CD11b-PE-Cyanine7 (clone M1 / 70, eBiosciences) clone 104, BD biosciences) were used. ^{Also, Lineage - / Sca-1 +} / c-kit + (LSK) to the cells was prepared using the MACS purification, TXNIP or p-p38, wherein -TXNIP (clone D5F3E, Cell Signaling) to the cells in the dyeing, Anti-rabbit IgG Alexa Fluor 647 (Life technology) or anti-phospho-p38-APC (clone 4NIT4KK, eBiosciences) was used.

LT-HSC is the most prominent blood-stem cell, capable of differentiating into all blood cells present in the body with self-replicating ability and sustaining hematopoietic action to permanently supplement the hematopoietic system. In contrast to LT-HSC, ST-HSC has a short duration of hematopoietic action, and MPP has the ability to differentiate into all blood cells present in the body, although it has the ability to differentiate into all the blood cells present in the body with self- , LT-HSC, and ST-HSC. In other words, LT-HSC, ST-HSC, and MPP decrease the self-replicating ability as stem cells.

In the case of normal rats, the number of LT-HSCs increases with age, and the ratio of LT-HSC in LSK (Lin (lineage) ^- / Sca-1 ⁺ / c-kit ⁺ the gatneunde, TXNIP ^{- / -} was the ratio of LT-HSC increased compared flow cytometry in mice results in TXNIP ^{+ / +} (12 months of age, Fig. 3B), LSK (Lin (lineage ) - / Sca-1 + / c-kit ⁺⁾ cells, i.e., LT-HSC, ST-HSC , MPP, the 12 months of age TXNIP ^{- / -} the ratio of the LT-HSC in mice is increased to roughly TXNIP ^{+ / +} 24 months of age similarly the ratio of MPP , And it was confirmed that HSN of TXNIP ^{- / -} was prematurely aged (FIG. 3C).

<1-2> TXNIP ^{- / -} of HSC  Confirmation of aging factor expression

To determine whether TXNIP inhibits the expression of senescence-related factors in HSCs, we measured levels of reactive oxygene species (ROS), known to be increased by senescence, in HSNs of TXNIP ^{- / -} mice, mRNA expression of p19, p21 and Wnt5a was confirmed using qPCR. For measurement of reactive oxygen species, bone marrow cells were immediately stained with a cell surface marker and reacted with active oxygen-specific probe CM-DCF-DA (Molecular Probes / Thermofisher Scientific) or Dihydroethidium (DHE, Molecular Probes / ThermoFisher Scientific) Followed by flow cytometry using FACSCanto II (BD Biosciences).

As a result, compared to the control group (TXNIP ^{+ / +} ) in HSC of 12 month old TXNIP ^{- / -} mice (Fig. 4A), and the expression of p16, p19, p21 and Wnt5a increased in a manner similar to that of 24-month old TXNIP ^{+ / +} HSC, which was already senescent (Figs. 4B to E). Thus, these results suggest that genetic defects of TXNIP are responsible for senescence of HSCs.

<1-3> TXNIP ^{- / -} Confirming inhibition of hematopoiesis

In order to confirm the role of TXNIP in hematopoietic function (hematopoiesis), the 5-FU (5-fluoracil, 150mg / kg) to induce acute leukopenia and the cells targeted circulating blood TXNIP ^{+ / +} and TXNIP ^{- / -} mice, and the number of leukocytes in the blood was checked for 17 days.

As a result, the number of leukocytes was gradually decreased in TXNIP ^{+ / +} and TXNIP ^{- / -} mice at 6 days, TXNIP ^{+ / +} mice recovered to normal state in 14 days, TXNIP ^{- / -} The mice did not recover and all TXNIP ^{- / -} mice died on day 17 (FIG. 5A, B).

In addition, a competitive transplantation assay was performed to identify the autonomous function of HSC cells. Bone marrow cells were extracted from young mice (young, 2 months old) ( CD45.2 ⁺ ) and LT-HSC isolated for competitive bone marrow transplantation analysis. 400-500 LT-HSCs were mixed with 1 x 10 ⁶ to 1.5 x 10 ⁶ competitor bone marrow cells (CD45.1 ⁺ ) to generate a lethally irradiated, 9Gy 6- And injected into the tail vein of congenic recipient (CD45.1 ⁺ ) mice. After 16 weeks, proliferating LT-HSC proliferation was analyzed by flow cytometry on peripheral blood or bone marrow cells from the tail vein. In order to confirm the level of active oxygen of LT-HSC, the bone marrow cells were stained with a cell surface marker immediately after extraction, and then an active oxygen-specific probe CM-DCF-DA (Molecular Probes / Thermofuser Scientific) or Dihydroethidium (DHE, / ThermoFisher Scientific) and analyzed by flow cytometry using FACSCanto II (BD Biosciences).

As a result, the engraftment of CD45.2 ⁺ HSC in the peripheral blood and bone marrow of transplanted HSCs derived from TXNIP ^{- / -} mice was markedly decreased (FIG. 5C, D). As shown in the above experiment, when HSCs of old age are transplanted into young donors, the tendency of B lymphocytes to be inhibited from engraftment and differentiate into myeloid lineages is called lineage skewing, and is an index of HSC aging It is known. As a result of flow cytometry analysis of HSC sequence defects in the above competitive transplantation, CD45.2 ⁺ cells derived from HSC of TXNIP ^{- / -} mice were analyzed by TXNIP ^{+ / +} It was confirmed that HSN of TXNIP ^{- / -} was senescent by observing that the differentiation into B lymphocytes (B220 ⁺ ) and T lymphocytes (CD3 ⁺ ) was decreased and the differentiation into myleoid was increased compared to CD45.2 ⁺ cells ). Also, TXNIP ^{- / -} was the one derived from HSC cells of the mice as compared to TXNIP ^{+ / +} CD45.2 ⁺ MPP LSK reduction of the cell to make sure that an increase of LT-HSC (FIG. 5F), TXNIP ^{- / -} mice From the above results, it can be seen that TXNIP is an adjuvant of hematopoiesis and that TXNIP deficiency ages HSC in LT-HSCs derived from HSC (Fig. 5G).

< Experimental Example  2> TNXIP ^{- / -} From HSC  Verify activation of p38

p38 is known to play an important role in the expression of senescence-related genes in cell signaling pathways and HSCs induced by oxidative stress. Therefore, in order to examine the association between p38 and aging of HSC, the present inventors have found that p38 isoform (α, beta, gamma, and delta) of mRNA expression.

As a result, it was confirmed that among the four p38 isoforms, p38α was mainly expressed and most predominantly expressed in LT-HSC (FIG. 6A).

In order to examine the relationship between p38 and TXNIP in HSC aging, p38 activity of each age group (2, 12 and 24 months) was confirmed in TXNIP ^{+ / +} and TXNIP ^{- / -} mice. For immunofluorescence staining, LT-HSCs isolated from bone marrow cells were placed on a cover glass coated with fibronectin, allowed to react at 4 ° C for 10 minutes, adhered, and punctured with 0.2% Triton X-100 solution. BSA in PBS for 30 min and then treated with anti-p38 or anti-TXNIP primary antibody for 1 hour at room temperature. After washing three times for 5 minutes with PBS, secondary antibody, Alexa Fluor 647 or Alexa Fluor 488 And incubated for 1 hour at room temperature. After washing three times for 5 minutes, the mounting solution containing DAPI was placed on a slide glass, fixed, and images were confirmed with a confocal microscope.

As a result, phosphorylation (p-p38) a reduction in the increase of age and TXNIP of the p38 protein (TXNIP ^{- / -)} Flow cytometric analysis (FIG. 6B) to be increased by, immunofluorescence (Fig. 6C), western blot (Fig. 6D). Also, by confirming that the expression of TXNIP in LT-HSC is increased at 24 months compared to 2 months (Fig. 6E), it is suggested from the above results that TXNIP and p38 are related to senescence in HSC.

< Experimental Example  3> From HSC TXNIP and  Identification of direct interaction of p38

We also performed immunoprecipitation and in situ proximity ligation (PLA) analyzes to determine whether TXNIP regulates the activity of p38 by p38 interaction. For in situ PLA analysis, HSC was treated with H ₂ O ₂ and sprinkled on a cover slip coated with fibronectin and allowed to react for 4 to 10 minutes. The in situ binding of TXNIP and p38 was performed using Duolink assay kit (Sigma) according to the manufacturer's instructions. The cells were stained with TXNIP antibody (MBL) and p38 antibody (Cell signaling), and stained with LSM510 confocal microscope (Carl Zeiss) . In the immunoprecipitation method, the bone marrow cells were separated, the cells were disrupted with a cell lysis solution, and the supernatant was separated by performing high-speed centrifugation. The protein concentration was measured and diluted to 500 μg / 500 μl, 10 μg / 500 μl, and then incubated at 4 ° C for 4 hours with 20 μl of protein A agarose bead capable of binding to the primary antibody. After washing three times with 1 ml of lysis solution, all lysis solutions were removed 25 μl of lysis solution and 5 × SDS sample solution were added, boiled at 100 ° C. for 3 minutes, electrophoresed on SDS-PAGE gel, and western blotted.

As a result, it was confirmed from the immunoprecipitation result that TXNIP and p38 were mutually linked (Fig. 7A), and it was confirmed from the PLA results that TXNIP and p38 were mutually linked (Fig. 7B).

To investigate the effect of ROS on the interaction of TXNIP and p38, we examined the expression of TXNIP and p-p38 by Western blotting after treatment with H ₂ O ₂ , and in situ PLA analysis The binding of TXNIP to p38 was confirmed.

As a result, in bone marrow cells, TXNIP increased very rapidly by H ₂ O ₂ (0.5 mM), became maximal at 15 min, then gradually decreased, and p-p38 increased by H ₂ O ₂ And maintained for up to 60 minutes (Fig. 7C). Also, in situ PLA analysis showed that treatment of young HSC with H ₂ O ₂ increased the PLA signal to the HSC level of the old, resulting in an increase in the interaction of TXNIP with p38 (FIG. 7D). In addition, GST-full down analysis was performed on HEK293T cells overexpressing TXNIP and p38, and the binding of TXNIP to p38 was increased by treatment with H ₂ O ₂ (0.5 or 1 mM) And it was confirmed that oxidative stress enhances the interaction of TXNIP and p38 (FIG. 7E).

Subsequently, four hydrophobic residues of TXNIP, considered as a potential binding domain (docking domain) to examine the essential amino acid residues of the TXNIP-p38 mutual binding, were subjected to 4 site-directed mutagenesis ), And the binding with p38 was confirmed by GST-full down analysis.

As a result, it can be seen that the positional mutants of the L290 and L292 residues completely decrease binding to p38 (Fig. 7F), so that L290 and L292 of TXNIP are important for mutual binding to p38. In addition, all of the binding domain variants of p38 showed decreased mutual binding to TXNIP (Figure 7G). The results suggest that TXNIP modulates the activity of p38 of HSC by binding directly to p38.

< Experimental Example  4> in in vivo  inhibiting the activity of p38 ROS  Reduce HSC Reverse aging  Confirm

To investigate the role of p38 in the rejuvenation of senescent HSCs, we used competitive transplantation using mice treated with TXNIP ^{- / -} / p38 ^{AF / +} mice (TXNIP knockout / p38 inactivated) or p38 inhibitor SB203580 And the engraftment of CD45.2 ⁺ LT-HSC in peripheral blood vessels was analyzed.

As a result, the characteristics of aging in young TXNIP ^{- / -} (TXNIP ^{- / -} 2M) (ie LT-HSC engraftment (TXNIP ^{- / -} / p38 ^{AF / +} or TXNIP ^{- / -} / SB) inhibited the aging characteristics of p38, (Fig. 9A. B). In addition, the composition of CD45.2 ⁺ LSK cells after competitive transplantation analysis showed that LT-HSC decreased and MPP increased (Fig. 9C) in TXNIP ^{- / -} / p38 ^{AF / +} or TXNIP ^{- / -} / SB, , confirming that p38 activity and active oxygen levels are low (Fig. 9D, E), demonstrating that inhibition of p38 prevents senescence of hematopoietic stem cells.

In addition, TXNIP ^{+ / +} , TXNIP ^{+ / +} / p38 ^{AF / + at} 2 months and 12 months, Analysis of leukocyte distribution in peripheral blood of TXNIP ^{- / -} and TXNIP ^{- / -} / p38 ^{AF / +} mice showed aging sequence bias in 12 months TXNIP ^{- / -} mice, but TXNIP ^{- / -} / p38 ^{AF / +} mice to the TXNIP ^{+ / +} mouse level (Fig. 9F).

In addition, when 5-FU was induced to induce acute leukopenia, the survival rate of TXNIP ^{- / -} mice gradually decreased and died after 18 days. Inhibition of p38 activity significantly increased the survival rate of TXNIP ^{- / -} mice (Fig. 9G), suggesting that p38 aged HSC and inhibition of p38 activity induced HSC rejuvenation.

< Experimental Example  5> TNXIP  origin Of peptide  Confirmation of p38 activity inhibition

The inhibition of P38 phosphorylation of TAT-TN13 peptide in aged bone marrow cells or HSCs resulted in inhibition of p-P38 and p-ATF2 expression in a concentration-dependent manner of TAT-TN13 peptide. Thus, TAT-TN13 peptide effectively inhibited P38 phosphorylation Inhibiting the activity of the enzyme (Fig. 8A).

In order to investigate the mechanism of p38 inhibition of TAT-TN13 peptide, another p38 kinase MKK3 or MKK6, which binds to p38, was overexpressed, treated with TAT-TN13 peptide and subjected to p38 protein and GST-full down analysis. -TN13 peptide inhibited the binding of p38 and MKK3 or p38 and MKK6 (Fig. 8B, C).

This result implies that the TAT-TN13 peptide shares the p38 docking site with MKK3 and MKK6 and interferes with the binding with the higher phosphorylating enzyme through mutual binding with p38, thereby inhibiting the activity of p38 phosphorylase. In addition, as shown in FIG. 8D, the p38 protein can be confirmed by immunoprecipitation of TXNIP in the TAT-TN13 peptide-untreated group, whereas when treated with 10 uM TAT-TN13, the p38 protein precipitation is markedly inhibited and TAT-TN13 Peptides and TXNIP competitively confirmed binding to p38. From the above results, it can be seen that TXNIP directly binds to p38 and inhibits its activity.

< Experimental Example  6> in vitro in TAT Due to -TN13 HSC Reverse aging  Confirm

To determine if inhibition of p38 with TAT-TN13 could restore the senescent HSC back to the young stage, 10 uM of TAT-TN13 was treated for 16 h with aged HSCs.

As a result, it was confirmed that TAT-TN13 inhibited p-p38 (Fig. 10A) and active oxygen (Fig. 10B) at a level similar to that of p38 inhibitor (SB203580) treatment in aged HSCs.

According to Florian et al., The polarity of Cdc42 is a marker of the age of HSC (lost polarity upon aging) and the pharmacological inhibition of Cdc42 induces the reverse aging of senescent HSCs (2013, Nature, 503, 392- 396).

In this experimental example, the polarity of Cdc42 was confirmed by immunofluorescence staining as an index of aging. Old HSCs were sprinkled on a coverslip coated with fibronectin and incubated for 4 to 10 minutes and fixed. Cells were treated with 10 uM TAT, TAT-TN13 or SB203580 for 16 h, and Cdc42 antibody (Cell signaling) , Alexa Fluor 546 antibody (Life technology), and DAPI containing mounting reagent (Molecular Probes). For the polarity analysis, polarizing trend of Cdc42 of 50 to 60 HSCs was confirmed with Confocal microscope.

As a result, most aged HSCs are depolarized (Old HSC-No, Old HSC-TAT), Suppressing p38 with TAT-TN13 or SB203580 reverses aging of HSC, (Fig. 10C).

In addition, TAT-TN13 or SB203580 was treated with old HSC and the expression of p16, p19, p21 and Wnt5a was confirmed by qPCR in order to confirm whether the inhibition of p38 activity induced HSC reverse aging. -term homing assay. CD45.2 ⁺ HSC was extracted immediately for 10 days, and TAT, TAT-TN13 (synthesized by Peptron) or SB203580 (Selleckchem) was treated and incubated for 16 hours at 37, 5% CO ₂ . Ten thousand each of the HSCs treated with TAT, TAT-TN13 or SB203580 or the control HSCs not treated with the drug were mixed with a congenic recipient (CD45.1) of lethally irradiated (9 Gy) 6-8 weeks old ⁺ ) Mice were injected into the tail vein. After 18 hours, bone marrow was collected from the recipient mice, stained with CD45.1 or CD45.2 antibody, and flow cytometry was performed to analyze the relative frequency of CD45.2 ⁺ cells in total bone marrow cells.

As a result, TAT-TN13 or SB203580 markedly decreased the expression of the senescence-related genes p16, p19, p21 and Wnt5a (Fig. 10D-G) and confirmed that the homing of HSC was increased (Fig. 10H) Inhibition of p38 activity by TAT-TN13 has been shown to induce reverse aging of HSCs.

< Experimental Example  7> in vivo in GFP -TN13 and TAT Aged by TN13 HSC Reverse aging  Confirm

TN13 to ensure that the peptide is applied in animals, while mice from the extracts CD45.2 ⁺ HSC, a lenti-viral vector 36 time to express the GFP-TN13 the GFP is a chemical bond, after having been infected three times, GFP ⁺ HSC And mixed with CD45.1 ⁺ bone marrow cells for competitive transplantation. As a control, a lenti-viral vector expressing only TN13-unconjugated GFP was used.

As a result, TN13 inhibits the aging phenomena observed in young TXNIP ^{- / -} mice (TXNIP ^{- / -} 2M-GFP) and older TXNIP ^{+ / +} mice (TXNIP ^{+ / +} Old-GFP). Specifically, the analysis of peripheral blood were compared with the proportion of CD45.2 ⁺ cells, little TXNIP ^{- / -} mice ^{(TXNIP - / - 2M-GFP} ) and a TXNIP ^{+ / +} mice (TXNIP ^{+ / +} Old-GFP aging ) decreased the engraftment of CD45.2 ⁺ in the reduction of the CD45.2 ⁺ TN13 is expressed (TXNIP ^{- / -} were increased by the 2M-GFP-TN13 or ^{TXNIP + / + Old-GFP-} TN13) ( Figure 11A ). In addition, the sequence bias analysis showed that inhibition of myeloid increase in TXNIP ^{- / -} 2M-GFP-TN13 and senescent TXNIP ^{+ / +} Old-GFP-TN13 in peripheral blood CD45.2 ⁺ (Fig. 11B) inhibited the increase of LT-HSC in CD45.2 ⁺ LSK cells and increased the reduced MPP, confirming that TN13 inhibited the tendency to senescence (Fig. 11C). In addition, it was confirmed that TN13 inhibited p38 and active oxygen in TXNIP ^{- / -} 2M-GFP-TN13 and TXNIP ^{+ / +} Old-GFP-TN13 (FIG. These results suggest that TN13 can inhibit senescence of HSCs.

in vivo In order to confirm the utility of TAT-TN13 as an anti-aging drug against aged HSCs, old TAT-TN13 treated HSC (TXNIP ^{+ / +} Old-TAT-TN13) or 12 months of TXNIP ^{- / -} HSC TXNIP ^{- / -} 12M-TAT-TN13) were competitively transplanted.

As a ^{result, TXNIP + / + Old-TAT} -TN13 or TXNIP ^{- / -} control group ^{12M-TAT-TN13 (TXNIP +} / + Old-TAT or ^{TXNIP - / - 12M-TAT)} CD45.2 + engraftment of the cells as compared to (Fig. 12A), the aged sequence bias tendency was restored to that of young TXNIP ^{+ / +} (Fig. 12B), the LT-HSC ratio in the CD45.2 ⁺ LSK cells decreased and the MPP ratio increased 12C), p-p38 and active oxygen were decreased (Fig. 11D, E), indicating that all of the aging characteristics in the control group changed to reverse aging characteristics. In addition, when TAT-TN13 (25 mg / kg) was administered daily for 4 days from day 1, acute leukopenia was induced by administering 5-FU (100 mg / kg) to aged TXNIP ⁺ (24M-TXNIP ^{+ / +} -TAT) showed a rapid increase in leukocyte count and a marked increase in leukocyte count in the TAT-TN13 treated group (24M-TXNIP ^{+ / +} TAT-TN13) has little TXNIP ^{+ / +} than the number of observed plenty, is stable after 10 days 13 days little ^{TXNIP + / + (TXNIP + /} + 2M) was maintained at the same level as (Fig. 12F). These results suggest that TAT-TN13 can be used as a drug to reverse aged HSCs.

< Experimental Example  8> p38 by TN13 MAPK  Active inhibition confirmation

In order to confirm selective inhibition of P38 phosphorylase activity of TAT-TN13 peptide in bone marrow cells, LGTSFKGKYGCVD (SEQ ID NO: 46) corresponding to amino acid sequence 110-122 of TXNIP at a position not involved in the interaction between TAT and TXNIP or P38 ) &Lt; / RTI &gt; peptide was prepared and tested as a control. The results obtained by Western blotting are shown in Fig. As shown in Fig. 13, it was confirmed that TAT-TN13 decreased the expression of p-P38 in a concentration-dependent manner. As a result, it was confirmed that the TAT-TN13 peptide selectively and effectively inhibited the activity of P38 phosphorylase.

< Experimental Example  9> Identification of anti-inflammatory effect by TN13

<9-1> Confirmation of inhibition of inflammatory cytokine secretion

TN13 peptides inhibited the secretion of inflammatory cytokines (IL-1β / IL-6 / TNF-α) into cells by enzyme-linked immunosorbent assay (ELISA). Raw 264.7 macrophages were plated on a 12-well plate at a density of 1 × 10 ⁶ cells / well and cultured for 2 hours. After that, the TN13 peptide was treated for each concentration and incubated for 1 hour. The IL-1β, IL-6 and TNF-α production levels were measured by taking the supernatant obtained by treating LPS at a concentration of 100 ng / . Cytokine was prepared by adding 100 μL of standard and samples prepared in 96-well plate coated with antibody to each cytokine, incubated for 2 hours at room temperature, washed three times, and then incubated with biotinylated antibody reagent The cells were washed three times with 100 μL of Streptavidin-HRP solution for 20 min. After washing three times, the TMB substrate solution was added to each well at 100 μL And reacted at room temperature in a dark place. Stop solution (0.16 M sulfuric acid) was added to each well to stop the reaction. The absorbance was measured at 450 nm using a UV / VIS spectrophotometer (SpectraMax i3x, Molecular Device, USA).

The results are shown in Fig.

IL-1β, IL-6, and TNF-α, which are expressed as inflammatory cytokines, are known to mediate inflammatory responses and are particularly involved in early inflammatory reactions. As shown in FIG. 14, TN13 peptide treatment significantly reduced IL-1β, IL-6 and TNF-α production in Raw264.7 macrophages induced by LPS-induced inflammation, as measured by the amount of inflammatory cytokine production . In particular, IL-1β, IL-6 and TNF-α production was inhibited by about 50% when treated with 20 μM TN13 peptide compared with LPS alone. Thus, it was confirmed that the TN13 peptide effectively inhibited the secretion of inflammatory cytokines.

<9-2> Inhibition of p38 MAP kinase, NF-kB (p65) and c-Jun activity

RAW264.7 cells were suspended in DMEM containing 10% FBS and incubated in 6 well plates (Corning, USA) at 5 × 10 5 cells / well in order to confirm that TN13 peptide inhibits p38 MAP kinase activation in RAW264.7 cells via LPS stimulation Cells were seeded at 10 ⁵ cells / ml in 2 ml each well and stabilized in a 5% CO ₂ incubator at 37 ° C for 2 hours. After exchanging with fresh DMEM medium, TN13 peptide was treated with cells (1/5/10/20, uM) for 1 hour. After the completion of the TN13 peptide reaction, LPS was added to the existing medium at a concentration of 100 ng / ml and stimulated for 30 minutes. After LPS stimulation, media were removed and washed with cold PBS. Cell lysates were extracted with Lysis buffer (+ 1% Triton X-100). Protein content was quantified by BCA protein assay (Thermo, USA) and 40 ug of protein was electrophoresed and transferred to Immobilon-PVDF membrane (Merck, USA). The transferred membrane was blocked with 5% skim milk dissolved in phosphate-buffered saline Tween-20 (PBST) (20 mM Tris, pH 7.6, 136 mM NaCl, 0.1% Tween 20) for 1 hour at room temperature. p65, anti-p65, anti-phospho-p38, anti-p38 MAP kinase, anti-phospho-c-Jun, anti-c-Jun and β- actin primary antibody (1: 1000 dilution) After washing three times with PBST, the cells were reacted with HRP-conjugated secondary antibody (1: 1000 dilution) for 1 hour at room temperature. After washing three times with PBST, the immunoreactive protein bands were detected using WSE-6200 LuminoGraph II (ATTO, Japan).

The results are shown in Fig.

 The activity of p38 MAP kinase is known to induce the activity of NF-kB (p65) and c-Jun, which are important transcription factors in inflammatory responses. As shown in Fig. 15, it was confirmed that the TN13 peptide effectively inhibited the activity of p38 MAP kinase, thereby inhibiting the activity of NF-kB (p65) and c-Jun.

<9-3> TN13 peptide inhibition of iNOS and COX-2 protein expression in macrophages

When inflammatory reaction occurs, inflammatory factors such as excessive nitric oxide (NO) and prostaglandin E2 (PGE 2) are formed by inducible NO synthase (iNOS) and cyclooxygenase (COX-2). To confirm the effect of TN13 peptide on these two proteins, RAW264.7 cells were suspended in DMEM containing 10% FBS, and the number of cells was 2.5 × 10 ⁵ cells / ml in 6-well plates (Corning, USA) 2 ml each was dispensed into each well and stabilized in a 5% CO 2 incubator at 37 ° C for 2 hours. After exchanging with fresh DMEM medium, TN13 peptide was treated with cells (1/5/10/20, uM) for 1 hour.

The results are shown in Fig.

As shown in FIG. 16, in the LPS-untreated group, the COX-2 protein was hardly expressed, whereas the expression was significantly increased in the LPS-treated group, and the TN13 peptide treatment was the Raw264.7 And inhibited the expression of iNOS and COX-2 protein effectively in phagocytes. The expression of iNOS and COX-2 protein was inhibited by the TN13 peptide. In particular, the expression of iNOS and COX-2 protein in the 20 μM TN13 peptide was inhibited by LPS Treatment group to the same level as the non - treatment group.

<9-4> TN13 peptide inhibition of NO production in macrophages

NO measurements were performed by dividing the cells into 48-well plates at a density of 1 × 10 ⁵ cells / well and incubating for 2 hours. TN13 peptide was treated at different concentrations (1/5/10/20 μM) well were treated with LPS at a concentration of 100 ng / mL and cultured for 24 hours. After the culture, 100 μL of the culture supernatant was taken and the NO level was measured by conducting the experiment according to the manual of Nitric Oxide detection kit (IntRON biotech.).

The results are shown in Fig.

As shown in FIG. 17, Raw 264.7 macrophages induced by LPS were significantly increased in NO production (10.433 μM), whereas Raw 264.7 macrophages treated with TN13 peptide (1-20 μM) Inhibited the production of NO. In particular, treatment with 20 μM TN13 peptide showed NO production close to the LPS-untreated normal group (0.35 μM).

As a result, it was confirmed that treatment with TN13 peptide effectively reduced production of NO when inflammation was induced.

< Experimental Example 10> to TN13  Of Osteoporosis Treatment

<10-1> Confirmation of inhibition of osteoclast differentiation by TN13

Raw 264.7 cells were seeded in 12-well plates at a density of 1 × 10 ⁵ / well and cultured in α-minimal essential medium (α-minimal essential medium) supplemented with 10% fetal bovine serum (FBS) and 1 × antibiotics, RANKL (40 ng / MEM) medium was treated with TN13 at a concentration of 10 [mu] M daily and cultured for 4 days. TN13 was treated with 10 μM every 2 days and stained with TRAP solution for 4 days to confirm osteoclast differentiation.

The results are shown in Fig. 18A.

As shown in Fig. 18A, it was confirmed that osteoclast-resistant acid phosphatase (TRAP) -positive cells in red purple color were identified as osteoclasts, and it was confirmed that osteoclast differentiation was suppressed by treatment with TN13.

8 weeks old female C57BL6 / J mice were sacrificed by cervical dislocation and bone marrow was collected from the tibia and femur. The red blood cells were removed from the collected bone marrow cells and cultured for one day in α-MEM medium supplemented with FBS, 1 × antibiotics and M-CSF (10 ng / ml). Only non-adherent cells without stromal cells were collected and cultured in 100 mm culture dishes for 3 days in α-MEM medium supplemented with FBS and 1 × antibiotics and M-CSF (20 ng / ml). After 3 days, the non-adherent cells were removed and the remaining adherent cells were used as bone marrow macrophages (BMMs) as osteoclast precursor cells. The macrophages were plated on a 24-well plate at a density of 5 × 10 ⁴ / well and cultured in α-MEM medium supplemented with FBS, 1 × antibiotics, M-CSF (30 ng / ㎖) and RANKL (50 ng / SB203580, an inhibitor of p38 MAPK, was treated with 10 [mu] M daily and cultured for 5 days. The culture medium was changed every 2 days to treat TN13 and p38 MAPK inhibitor SB203580 at 10 μM daily, and stained with TRAP solution for 5 days to identify osteoclasts.

The results are shown in Fig. 18B.

As shown in Fig. 18B, when osteoclast-positive TRAP (tartrate-resistant acid phosphatase) -positive cells were identified as osteoclasts, it was confirmed that osteoclast differentiation was inhibited by treatment with TN13, which is similar to that of the positive control group Respectively.

<10-2> Identification of treatment effect in animal model of osteoporosis

The treatment effect of osteoporosis according to TN13 treatment was confirmed.

The experiment schedule is shown in Fig. 19A. Experimental animals were divided into three groups by purchasing eight-week-old C57BL6 / J female mice purchased from Dual Corporation. To make osteoporosis model, we performed incision of skin, muscle, and peritoneum of lower abdomen after general anesthesia. Both ovaries were exposed, ovary was cut, and each layer of peritoneum, muscle and skin was closed with No. 4 silk (ovariectomy, OVX). The experimental material was administered after 1 week recovery period. TN13 was administered at vehicle dose of 25 mg / kg as a control group in the abdominal cavity using a 1 cc syringe every other day for 6 weeks. Six weeks later, the mice were sacrificed by cervical dislocation and the femur was obtained and fixed with 4% formaldehyde. Three-dimensional images (micro-CT) of the inside of the femur were obtained using micro-CT, and the bone mineral density and number of soju bone in the prepared tissue of the right femur. Bone surface, bone volume / total volume, bone surface / total volume were measured histomorphologically.

The results are shown in Fig. 19B.

As shown in Fig. 19B, it was confirmed that when TN13 was administered intraperitoneally at a dose of 25 mg / kg, the bone mineral density of the three-dimensional image of the femur was restored to that of the vehicle-treated group.

The upper animal model was used to confirm the changes in bone mineral density, number of soju bones, bone surface, bone volume / total volume, and bone surface / total volume. Cells were fixed with 4% formaldehyde for 1 min, washed with distilled water, and incubated with 2% Fast Garnet GBC base solution (Sigma, MO, USA) and sodium nitrite solution (Sigma, MO, USA), 2% Tartrate solution (Sigma, MO, USA) and 5% Naphthol AS-BI phosphoric acid USA). The cells were stained in a water bath at 37 ° C for 1 hour, washed with distilled water, and then stained with red cells by a microscope.

The results are shown in Fig.

As shown in Fig. 20, the bone mineral density (Fig. 3A, TN13), the number of soju bones (Fig. 3B, TN13), the bone surface (Fig. 3C and TN13), the bone volume / 3D, TN13) and bone surface / total volume (Fig. 3E, TN13).

These results confirm that TN13 can be used as a therapeutic agent for the treatment of osteoporosis.

<110> Korea Research Institute of Bioscience and Biotechnology <120> Composition comprising peptide derived from          thioredoxin-interacting protein or polynucleotide encoding the          peptide for rejuvenation of stem cell <130> P17024-KRI <150> KR 10-2016-0121312 <151> 2016-09-22 <160> 46 <170> Kopatentin 3.0 <210> 1 <211> 168 <212> PRT <213> Artificial Sequence <220> <223> GST-TXNIP-T <400> 1 Asp Val Asn Thr Pro Asp Leu Met Ala Pro Val Ser Ala Lys Lys Glu   1 5 10 15 Lys Lys Val Ser Cys Met Phe Ile Pro Asp Gly Arg Val Val Ser Ser              20 25 30 Ala Arg Ile Asp Arg Lys Gly Phe Cys Glu Gly Asp Glu Ile Ser Ile          35 40 45 His Ala Asp Phe Glu Asn Thr Cys Ser Arg Ile Val Val Pro Lys Ala      50 55 60 Ala Ile Val Ala Arg His Thr Tyr Leu Ala Asn Gly Gln Thr Lys Val  65 70 75 80 Leu Thr Gln Lys Leu Ser Ser Val Arg Gly Asn His Ile Ile Ser Gly                  85 90 95 Thr Cys Ala Ser Trp Arg Gly Lys Ser Leu Arg Val Gln Lys Ile Arg             100 105 110 Pro Ser Ile Leu Gly Cys Asn Ile Leu Arg Val Glu Tyr Ser Leu Leu         115 120 125 Ile Tyr Val Ser Val Pro Gly Ser Lys Lys Val Ile Leu Asp Leu Pro     130 135 140 Leu Val Ile Gly Ser Ser Ser Gly Leu Ser Ser Arg Thr Ser Ser Met 145 150 155 160 Ala Ser Arg Thr Ser Ser Glu Met                 165 <210> 2 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> TN12 <400> 2 Gly Ser Lys Lys Val Ile Leu Asp Leu Pro Leu Val   1 5 10 <210> 3 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> TN13 <400> 3 Gly Ser Lys Lys Val Ile Leu Asp Leu Pro Leu Val Ile   1 5 10 <210> 4 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> TN14 <400> 4 Gly Ser Lys Lys Val Ile Leu Asp Leu Pro Leu Val Ile Gly   1 5 10 <210> 5 <211> 15 <212> PRT <213> Artificial Sequence <220> <223> TN15 <400> 5 Gly Ser Lys Lys Val Ile Leu Asp Leu Pro Leu Val Ile Gly Ser   1 5 10 15 <210> 6 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> MKK6 <400> 6 Ser Lys Gly Lys Lys Arg Asn Pro Gly Leu Lys Ile Pro Lys Glu Ala   1 5 10 15 <210> 7 <211> 15 <212> PRT <213> Artificial Sequence <220> <223> MKK3b <400> 7 Gly Lys Ser Lys Arg Lys Lys Asp Leu Arg Ile Ser Cys Asn Ser   1 5 10 15 <210> 8 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> MEF2A <400> 8 Arg Lys Pro Asp Leu Arg Val Valle Pro Pro Ser Ser   1 5 10 <210> 9 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> HIV TAT domain <400> 9 Tyr Gly Arg Lys Lys Lys Arg Arg Gln Arg Arg Arg   1 5 10 <210> 10 <211> 2983 <212> RNA <213> Homo sapiens <400> 10 gtggctcttc tggcccgggc tactatatag agacgtttcc gcctcctgct tgaaactaac 60 ccctcttttt ctccaaagga gtgcttgtgg agatcggatc ttttctccag caattggggg 120 aaagaaggct ttttctctga attagcttag tgtaaccagc ggcgtatatt ttttaggcgc 180 cttttcgaaa acctagtagt taatattcat ttgtttaaat cttattttat ttttaagctc 240 aaactgctta agaatacctt aattccttaa agtgaaataa ttttttgcaa aggggtttcc 300 tcgatttgga gctttttttt tcttccaccg tcatttctaa ctcttaaaac caactcagtt 360 ccatcatggt gatgttcaag aagatcaagt cttttgaggt ggtctttaac gaccctgaaa 420 aggtgtacgg cagtggcgag aaggtggctg gccgggtgat agtggaggtg tgtgaagtta 480 ctcgtgtcaa agccgttagg atcctggctt gcggagtggc taaagtgctt tggatgcagg 540 gatcccagca gtgcaaacag acttcggagt acctgcgcta tgaagacacg cttcttctgg 600 aagaccagcc aacaggtgag aatgagatgg tgatcatgag acctggaaac aaatatgagt 660 acaagttcgg ctttgagctt cctcaggggc ctctgggaac atccttcaaa ggaaaatatg 720 ggtgtgtaga ctactgggtg aaggcttttc ttgaccgccc gagccagcca actcaagaga 780 caaagaaaaa ctttgaagta gtggatctgg tggatgtcaa tacccctgat ttaatggcac 840 ctgtgtctgc taaaaaagaa aagaaagttt cctgcatgtt cattcctgat gggcgggtgt 900 ctgtctctgc tcgaattgac agaaaaggat tctgtgaagg tgatgagatt tccatccatg 960 ctgactttga gaatacatgt tcccgaattg tggtccccaa agctgccatt gtggcccgcc 1020 acacttacct tgccaatggc cagaccaagg tgctgactca gaagttgtca tcagtcagag 1080 gcaatcatat tatctcaggg acatgcgcat catggcgtgg caagagcctt cgggttcaga 1140 agatcaggcc ttctatcctg ggctgcaaca tccttcgagt tgaatattcc ttactgatct 1200 atgttagcgt tcctggatcc aagaaggtca tccttgacct gcccctggta attggcagca 1260 gatcaggtct aagcagcaga acatccagca tggccagccg aaccagctct gagatgagtt 1320 gggtagatct gaacatccct gataccccag aagctcctcc ctgctatatg gatgtcattc 1380 ctgaagatca ccgattggag agcccaacca ctcctctgct agatgacatg gatggctctc 1440 aagacagccc tatctttatg tatgcccctg agttcaagtt catgccacca ccgacttata 1500 ctgaggtgga tccctgcatc ctcaacaaca atgtgcagtg agcatgtgga agaaaagaag 1560 cagctttacc tacttgtttc tttttgtctc tcttcctgga cactcacttt ttcagagact 1620 caacagtctc tgcaatggag tgtgggtcca ccttagcctc tgacttccta atgtaggagg 1680 tggtcagcag gcaatctcct gggccttaaa ggatgcggac tcatcctcag ccagcgccca 1740 tgttgtgata caggggtgtt tgttggatgg gtttaaaaat aactagaaaa actcaggccc 1800 atccattttc tcagatctcc ttgaaaattg aggccttttc gatagtttcg ggtcaggtaa 1860 aaatggcctc ctggcgtaag cttttcaagg ttttttggag gctttttgta aattgtgata 1920 ggaactttgg accttgaact tacgtatcat gtggagaaga gccaatttaa caaactagga 1980 agatgaaaag ggaaattgtg gccaaaactt tgggaaaagg aggttcttaa aatcagtgtt 2040 tcccctttgt gcacttgtag aaaaaaaaga aaaaccttct agagctgatt tgatggacaa 2100 tggagagagc tttccctgtg attataaaaa aggaagctag ctgctctacg gtcatctttg 2160 cttagagtat actttaacct ggcttttaaa gcagtagtaa ctgccccacc aaaggtctta 2220 aaagccattt ttggagccta ttgcactgtg ttctcctact gcaaatattt tcatatggga 2280 ggatggtttt ctcttcatgt aagtccttgg aattgattct aaggtgatgt tcttagcact 2340 ttaattcctg tcaaattttt tgttctcccc ttctgccatc ttaaatgtaa gctgaaactg 2400 gtctactgtg tctctagggt taagccaaaa gacaaaaaaa attttactac ttttgagatt 2460 gccccaatgt acagaattat ataattctaa cgcttaaatc atgtgaaagg gttgctgctg 2520 tcagccttgc ccactgtgac ttcaaaccca aggaggaact cttgatcaag atgcccaacc 2580 ctgtgatcag aacctccaaa tactgccatg agaaactaga gggcaggtct tcataaaagc 2640 cctttgaacc cccttcctgc cctgtgttag gagataggga tattggcccc tcactgcagc 2700 tgccagcact tggtcagtca ctctcagcca tagcactttg ttcactgtcc tgtgtcagag 2760 cactgagctc cacccttttc tgagagttat tacagccaga aagtgtgggc tgaagatggt 2820 tggtttcatg tttttgtatt atgtatcttt ttgtatggta aagactatat tttgtactta 2880 accagatata tttttacccc agatggggat attctttgta aaaaatgaaa ataaagtttt 2940 tttaatggaa aaaaaaatgt ctgtgaaaaa aaaaaaaaaaaaa 2983 <210> 11 <211> 4353 <212> RNA <213> Homo sapiens <400> 11 ttctctcacg aagccccgcc cgcggagagg ttccatattg ggtaaaatct cggctctcgg 60 agagtcccgg gagctgttct cgcgagagta ctgcgggagg ctcccgtttg ctggctcttg 120 gaaccgcgac cactggagcc ttagcgggcg cagcagctgg aacgggagta ctgcgacgca 180 gcccggagtc ggccttgtag gggcgaaggt gcagggagat cgcggcgggc gcagtcttga 240 gcgccggagc gcgtccctgc ccttagcggg gcttgcccca gtcgcagggg cacatccagc 300 cgctgcggct gacagcagcc gcgcgcgcgg gagtctgcgg ggtcgcggca gccgcacctg 360 cgcgggcgac cagcgcaagg tccccgcccg gctgggcggg cagcaagggc cggggagagg 420 gtgcgggtgc aggcgggggc cccacagggc caccttcttg cccggcggct gccgctggaa 480 aatgtctcag gagaggccca cgttctaccg gcaggagctg aacaagacaa tctgggaggt 540 gcccgagcgt taccagaacc tgtctccagt gggctctggc gcctatggct ctgtgtgtgc 600 tgcttttgac acaaaaacgg ggttacgtgt ggcagtgaag aagctctcca gaccatttca 660 gtccatcatt catgcgaaaa gaacctacag agaactgcgg ttacttaaac atatgaaaca 720 tgaaaatgtg attggtctgt tggacgtttt tacacctgca aggtctctgg aggaattcaa 780 tgatgtgtat ctggtgaccc atctcatggg ggcagatctg aacaacattg tgaaatgtca 840 gaagcttaca gatgaccatg ttcagttcct tatctaccaa attctccgag gtctaaagta 900 tatacattca gctgacataa ttcacaggga cctaaaacct agtaatctag ctgtgaatga 960 agactgtgag ctgaagattc tggattttgg actggctcgg cacacagatg atgaaatgac 1020 aggctacgtg gccactaggt ggtacagggc tcctgagatc atgctgaact ggatgcatta 1080 caaccagaca gttgatattt ggtcagtggg atgcataatg gccgagctgt tgactggaag 1140 aacattgttt cctggtacag accatattga tcagttgaag ctcattttaa gactcgttgg 1200 aaccccaggg gctgagcttt tgaagaaaat ctcctcagag tctgcaagaa actatattca 1260 gtctttgact cagatgccga agatgaactt tgcgaatgta tttattggtg ccaatcccct 1320 ggctgtcgac ttgctggaga agatgcttgt attggactca gataagagaa ttacagcggc 1380 ccaagccctt gcacatgcct actttgctca gtaccacgat cctgatgatg aaccagtggc 1440 cgatccttat gatcagtcct ttgaaagcag ggacctcctt atagatgagt ggaaaagcct 1500 gacctatgat gaagtcatca gctttgtgcc accacccctt gaccaagaag agatggagtc 1560 ctgagcacct ggtttctgtt ctgttgatcc cacttcactg tgaggggaag gccttttcac 1620 gggaactctc caaatattat tcaagtgcct cttgttgcag agatttcctc catggtggaa 1680 gggggtgtgc gtgcgtgtgc gtgcgtgtta gtgtgtgtgc atgtgtgtgt ctgtctttgt 1740 gggagggtaa gacaatatga acaaactatg atcacagtga ctttacagga ggttgtggat 1800 gctccagggc agcctccacc ttgctcttct ttctgagagt tggctcaggc agacaagagc 1860 tgctgtcctt ttaggaatat gttcaatgca aagtaaaaaa atatgaattg tccccaatcc 1920 cggtcatgct tttgccactt tggcttctcc tgtgacccca ccttgacggt ggggcgtaga 1980 cttgacaaca tcccacagtg gcacggagag aaggcccata ccttctggtt gcttcagacc 2040 tgacaccgtc cctcagtgat acgtacagcc aaaaaggacc aactggcttc tgtgcactag 2100 cctgtgatta acttgcttag tatggttctc agatcttgac agtatatttg aaactgtaaa 2160 tatgtttgtg ccttaaaagg agagaagaaa gtgtagatag ttaaaagact gcagctgctg 2220 aagttctgag ccgggcaagt cgagagggct gttggacagc tgcttgtggg cccggagtaa 2280 tcaggcagcc ttcataggcg gtcatgtgtg catgtgagca catgcgtata tgtgcgtctc 2340 tctttctccc tcacccccag gtgttgccat ttctctgctt acccttcacc tttggtgcag 2400 aggtttcttg aatatctgcc ccagtagtca gaagcaggtt cttgatgtca tgtacttcct 2460 gtgtactctt tatttctagc agagtgagga tgtgttttgc acgtcttgct atttgagcat 2520 gcacagctgc ttgtcctgct ctcttcagga ggccctggtg tcaggcaggt ttgccagtga 2580 agacttcttg ggtagtttag atcccatgtc acctcagctg atattatggc aagtgatatc 2640 acctctcttc agcccctagt gctattctgt gttgaacaca attgatactt caggtgcttt 2700 tgatgtgaaa atcatgaaaa gaggaacagg tggatgtata gcatttttat tcatgccatc 2760 tgttttcaac caactatttt tgaggaatta tcatgggaaa agaccagggc ttttcccagg 2820 aatatcccaa acttcggaaa caagttattc tcttcactcc caataactaa tgctaagaaa 2880 tgctgaaaat caaagtaaaa aattaaagcc cataaggcca gaaactcctt ttgctgtctt 2940 tctctaaata tgattacttt aaaataaaaa agtaacaagg tgtcttttcc actcctatgg 3000 aaaagggtct tcttggcagc ttaacattga cttcttggtt tggggagaaa taaattttgt 3060 ttcagaattt tgtatattgt aggaatcctt tgagaatgtg attccttttg atggggagaa 3120 agggcaaatt attttaatat tttgtatttt caactttata aagataaaat atcctcaggg 3180 gtggagaagt gtcgttttca taacttgctg aatttcaggc attttgttct acatgaggac 3240 tcatatattt aagccttttg tgtaataaga aagtataaag tcacttccag tgttggctgt 3300 gtgacagaat cttgtatttg ggccaaggtg tttccatttc tcaatcagtg cagtgataca 3360 tgtactccag agggacaggg tggaccccct gagtcaactg gagcaagaag gaaggaggca 3420 gactgatggc gattccctct cacccgggac tctccccctt tcaaggaaag tgaaccttta 3480 aagtaaaggc ctcatctcct ttattgcagt tcaaatcctc accatccaca gcaagatgaa 3540 ttttatcagc catgtttggt tgtaaatgct cgtgtgattt cctacagaaa tactgctctg 3600 aatattttgt aataaaggtc tttgcacatg tgaccacata cgtgttagga ggctgcatgc 3660 tctggaagcc tggactctaa gctggagctc ttggaagagc tcttcggttt ctgagcataa 3720 tgctcccatc tcctgatttc tctgaacaga aaacaaaaga gagaatgagg gaaattgcta 3780 ttttatttgt attcatgaac ttggctgtaa tcagttatgc cgtataggat gtcagacaat 3840 accactggtt aaaataaagc ctatttttca aatttagtga gtttctcaag tttattatat 3900 ttttctcttg tttttattta atgcacaata tggcattata tcaatatcct ttaaactgtg 3960 acctggcata cttgtctgac agatcttaat actactccta acatttagaa aatgttgata 4020 aagcttctta gttgtacatt ttttggtgaa gagtatccag gtctttgctg tggatgggta 4080 aagcaaagag caaatgaacg aagtattaag cattggggcc tgtcttatct acactcgagt 4140 gtaagagtgg ccgaaatgac agggctcagc agactgtggc ctgagggcca aatctggccc 4200 accacctgtt tggtgtagcc tgctaagaat ggcttttaca tttttaaatg gttgggaaag 4260 aaaaaaaaag aagtagtaga ttttgtagca tgtgatgtaa gtaatgtaaa acttaaattc 4320 cagtatccat aaataaagtt ttatgagaac aga 4353 <210> 12 <211> 32 <212> DNA <213> Artificial Sequence <220> <223> TXNIP (V178A / V180A) F <400> 12 ctgatgggcg ggcgtctgcc tctgctcgaa tt 32 <210> 13 <211> 33 <212> DNA <213> Artificial Sequence <220> <223> TXNIP (V178A / V180A) R <400> 13 aattcgagca gaggcagacg cccgcccatc agg 33 <210> 14 <211> 33 <212> DNA <213> Artificial Sequence <220> &Lt; 223 > TXNIP (I208A / V210A) F <400> 14 acatgttccc gagctgtggc ccccaaagct gcc 33 <210> 15 <211> 33 <212> DNA <213> Artificial Sequence <220> &Lt; 223 > TXNIP (I208A / V210A) R <400> 15 ggcagctttg ggggccacag ctcgggaaca tgt 33 <210> 16 <211> 33 <212> DNA <213> Artificial Sequence <220> &Lt; 223 > TXNIP (I278A / V280A) F <400> 16 tattccttac tggcctatgc tagcgttcct gga 33 <210> 17 <211> 33 <212> DNA <213> Artificial Sequence <220> &Lt; 223 > TXNIP (I278A / V280A) R <400> 17 tccaggaacg ctagcatagg ccagtaagga ata 33 <210> 18 <211> 33 <212> DNA <213> Artificial Sequence <220> &Lt; 223 > TXNIP (L290A / L292A) F <400> 18 aagaaggtca tcgctgacgc gcccctggta att 33 <210> 19 <211> 32 <212> DNA <213> Artificial Sequence <220> &Lt; 223 > TXNIP (L290A / L292A) R <400> 19 attaccaggg gcgcgtcagc gatgaccttc tt 32 <210> 20 <211> 27 <212> DNA <213> Artificial Sequence <220> <223> p38 (I116A) F <400> 20 gatctgaaca acgctgtgaa atgtcag 27 <210> 21 <211> 27 <212> DNA <213> Artificial Sequence <220> <223> p38 (I116A) R <400> 21 ctgacatttc acagcgttgt tcagatc 27 <210> 22 <211> 27 <212> DNA <213> Artificial Sequence <220> <223> p38 (Q120A) F <400> 22 attgtgaaat gtgcgaagct tacagat 27 <210> 23 <211> 27 <212> DNA <213> Artificial Sequence <220> <223> p38 (Q120A) R <400> 23 atctgtaagc ttcgcacatt tcacaat 27 <210> 24 <211> 30 <212> DNA <213> Artificial Sequence <220> <223> p38 (E160A / D161A) F <400> 24 ctagctgtga atgcagcctg tgagctgaag 30 <210> 25 <211> 30 <212> DNA <213> Artificial Sequence <220> <223> p38 (E160A / D161A) R <400> 25 cttcagctca caggctgcat tcacagctag 30 <210> 26 <211> 36 <212> DNA <213> Artificial Sequence <220> <223> p38 (D313A / D315A / D316A) F <400> 26 gctcagtacc acgctcctgc tgctgaacca gtggcc 36 <210> 27 <211> 36 <212> DNA <213> Artificial Sequence <220> <223> p38 (D313A / D315A / D316A) R <400> 27 ggccactggt tcagcagcag gagcgtggta ctgagc 36 <210> 28 <211> 27 <212> DNA <213> Artificial Sequence <220> <223> p38AF F <400> 28 gatgaaatgg caggcttcgt ggccact 27 <210> 29 <211> 27 <212> DNA <213> Artificial Sequence <220> <223> p38AF R <400> 29 agtggccacg aagcctgcca tttcatc 27 <210> 30 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> TXNIP F <400> 30 tgacctaatg gcaccagtgt 20 <210> 31 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> TXNIP R <400> 31 gccattggca aggtaagtgt 20 <210> 32 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> p16 F <400> 32 cgaactcttt cggtcgtacc 20 <210> 33 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> p16 R <400> 33 cgaatctgca ccgtagttga 20 <210> 34 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> p19 F <400> 34 gctctggctt tcgtgaacat 20 <210> 35 <211> 21 <212> DNA <213> Artificial Sequence <220> <223> p19 R <400> 35 tcgaatctgc accgtagttg a 21 <210> 36 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> p21 F <400> 36 ctgtcttgca ctctggtgtc 20 <210> 37 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> p21 R <400> 37 ccaatctgcg cttggagtga 20 <210> 38 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Wnt5a F <400> 38 ctctagcgtc cacgaactcc 20 <210> 39 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Wnt5a R <400> 39 caaataggca gccgagagac 20 <210> 40 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> beta actin F <400> 40 ctcctgagcg caagtactct 20 <210> 41 <211> 19 <212> DNA <213> Artificial Sequence <220> <223> beta actin R <400> 41 taaacgcagc tcagtaaca 19 <210> 42 <211> 36 <212> DNA <213> Artificial Sequence <220> <223> TN12 nucleotide <400> 42 ggatccaaga aggtcatcct tgacctgccc ctggta 36 <210> 43 <211> 39 <212> DNA <213> Artificial Sequence <220> <223> TN13 nucleotide <400> 43 ggatccaaga aggtcatcct tgacctgccc ctggtaatt 39 <210> 44 <211> 42 <212> DNA <213> Artificial Sequence <220> <223> TN14 nucleotide <400> 44 ggatccaaga aggtcatcct tgacctgccc ctggtaattg gc 42 <210> 45 <211> 45 <212> DNA <213> Artificial Sequence <220> <223> TN15 nucleotide <400> 45 ggatccaaga aggtcatcct tgacctgccc ctggtaattg gcagc 45 <210> 46 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> TN13C <400> 46 Leu Gly Thr Ser Phe Lys Gly Lys Tyr Gly Cys Val Asp   1 5 10

Claims (13)

A fusion peptide comprising a peptide comprising any one selected from the amino acid sequences represented by SEQ ID NOs: 2, 3, 4, and 5 and a TAT peptide comprising the sequence of SEQ ID NO: 9. The fusion peptide according to claim 1, wherein the fusion peptide comprises a peptide comprising the amino acid sequence of SEQ ID NO: 3 and a TAT peptide comprising the sequence of SEQ ID NO: A peptide comprising any one selected from the amino acid sequences represented by SEQ ID NOS: 2, 3, 4, and 5; 4. The composition of claim 3, wherein the peptide further comprises a TAT peptide consisting of the sequence set forth in SEQ ID NO: 9. A peptide comprising any one selected from the amino acid sequences represented by SEQ ID NOS: 2, 3, 4, and 5;
6. The composition according to claim 5, wherein the peptide further comprises a TAT peptide consisting of the sequence of SEQ ID NO: 9. A peptide comprising any one selected from the amino acid sequences represented by SEQ ID NOS: 2, 3, 4, and 5; and a pharmaceutical composition for preventing and treating an aging disease. 8. The pharmaceutical composition according to claim 7, wherein the peptide further comprises a TAT peptide consisting of the sequence of SEQ ID NO: 9. The composition for preventing and treating geriatric diseases according to claim 7, wherein the geriatric disease is selected from the group consisting of dementia, hypertension, Parkinson's disease, diabetes, cataract, osteoporosis, stroke, periodontal disease and degenerative arthritis . A peptide comprising any one selected from the amino acid sequences represented by SEQ ID NOS: 2, 3, 4, and 5; 11. The composition for preventing and treating inflammatory diseases according to claim 10, wherein the peptide further comprises a TAT peptide consisting of the sequence of SEQ ID NO: 1) treating a test substance with stem cells lacking a thioredoxin-interacting protein (TXNIP); And
2) selecting a test substance exhibiting any one or more characteristics selected from the group consisting of the following items a to d as compared to a control group not treated with the test substance;
a. reduction of expression or activity of p16, p19, p21 or Wnt5a gene;
b. reduction of phosphorylation of p38;
c. Reduced levels of reactive oxygen species (ROS); And
d. Increasing the polarity of Cdc42 (cell division control protein 42 homolog);
A method for screening a drug for inhibiting stem cell senescence. A peptide comprising any one selected from the amino acid sequences represented by SEQ ID NOS: 2, 3, 4, and 5;

Images